|
Tip |
Yayın |
| 58 |
Dergi |
Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161. |
| 201 |
Dergi |
Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531. |
| 226 |
Dergi |
Walker SE, DeAngelis C, Iazzetta J.
Stability and compatibility of combinations of hydromorphone and a second drug.
Can J Hosp Pharm 1991 ; 44: 289-295. |
| 266 |
Dergi |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 300 |
Dergi |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Dergi |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 349 |
Dergi |
Nahata MC, Hipple TF, Strausbaugh SD.
Stability of phenobarbital sodium diluted in 0.9% sodium chloride injection.
Am J Hosp Pharm 1986 ; 43: 384-385. |
| 642 |
Dergi |
Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA.
Norepinephrine stability in saline solutions.
Hosp Pharm 1988 ; 23: 44,49, 59. |
| 660 |
Dergi |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 921 |
Dergi |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1057 |
Dergi |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1072 |
Dergi |
Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
| 1412 |
Dergi |
Brett A, Riggs RM, Webster AA, Benner KW.
Y-site stability of fosphenytoin and sodium phenobarbital.
Int J Pharm Compound 1999 ; 3: 64-66. |
| 1415 |
Dergi |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1625 |
Dergi |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1802 |
Dergi |
Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194. |
| 1925 |
Dergi |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1974 |
Dergi |
Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171. |
| 2090 |
Dergi |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2262 |
Dergi |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 3379 |
Dergi |
Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524. |
| 3408 |
Dergi |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3501 |
Laboratuar |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics
Pfizer 2011 |
| 3525 |
Laboratuar |
Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012 |
| 3526 |
Laboratuar |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3531 |
Laboratuar |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014 |
| 3596 |
Laboratuar |
Chlorpromazine (Largactil®) - Summary of Product Characteristics
Sanofi 2014 |
| 3631 |
Laboratuar |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit
Aguettant 2016 |
| 3674 |
Laboratuar |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3676 |
Laboratuar |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit
Hospira 2014 |
| 4009 |
Laboratuar |
Droperidol - Résumé des Caractéristiques du Produit
Panpharma 2017 |
| 4419 |
Dergi |
Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161. |
| 4435 |
Dergi |
Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27. |
| 4543 |
Dergi |
Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295. |
| 4700 |
Laboratuar |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics
AS Kalceks 2022 |
| 4742 |
Dergi |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
